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ABSTRACT:
p53 and p63 are transcription factors -TFs- playing master roles in the DNA-damage 
response and in the development and maintenance of pluristratified epithelia, 
respectively. p53 mutations are common in epithelial tumors and HaCaT keratinocytes 
harbor two p53 alleles -H179Y and R282Q- with gain-of-function (GOF) activity. 
Indeed, functional inactivation of mutp53 affects the growth rate of HaCaT. We 
investigated the strategy of mutp53, by performing ChIP-Seq experiments of mutp53 
and p63 and analyzed the transcriptome after mutp53 inactivation. Mutp53 bind to 
7135 locations in vivo, with a robust overlap with p63. De novo motifs discovery 
recovered a p53/p63RE with high information content in sites bound by p63 and 
mutp53/p63, but not by mutp53 alone: these sites are rather enriched in elements of 
other TFs. The HaCaT p63 locations are only partially overlapping with those of normal 
keratinocytes; importantly, and enriched in mutp53 sites which delineate a functionally 
different group of target genes. Our data favour a model whereby mutp53 GOF mutants 
act both by tethering growth-controlling TFs and highjacking p63 to new locations.
INTRODUCTION
p53/p63/p73 are a family of transcription factors 
-TFs- that share a conserved DNA-binding domain and a 
similar DNA target sequence in promoters and enhancers 
[1-4]. p63 is involved in the development and maintenance 
of the skin and of pluristratified epithelia. The major 
isoform present in the skin -DeltaNp63alpha- is essential 
for development of ectoderm and stratification, through 
activation of the epithelial cell adhesion program, and 
it plays a major role in maintaining the proliferative 
potential of stem cells [3]. p63 is overexpressed in many 
epithelial tumors, notably Squamous Cell Carcinomas, 
SCC [4]. The risk of developing SCC is directly related 
to UV exposure and mutations in p53 are clearly a 
predisposing factor: indeed UVB “signature” mutations 
were reported [5]. HaCaT cells are immortalized, non 
tumorigenic keratinocytes with mutant p53 alleles, R282Q 
and H179Y [6], which are typical UVB signatures [7]. In 
this system, the p53 pathway is functional in response to 
UVB irradiation, in terms of cell cycle block and induction 
of apoptosis [8, 9]. These cells also express large amounts 
of DeltaNp63alpha.
Abolition of the p53 powerful tumor suppression 
functions is an important step in cancer progression, and 
the location of hotspot mutations in residues important 
for DNA-binding provided a conceptual framework 
pointing at a loss-of-function mechanism. However, there 
is now strong genetic evidence that some p53 missense 
mutants are pro-active in tumor progression and metastasis 
formation [Reviewed in 10, 11]. The issue of the interplay 
between mutp53 and p63/p73 is quite relevant, because 
genetic experiments suggest a complex role of p63 
isoforms in transformation [4], and p53 missense mutants, 
including those produced by HaCaT alleles, have an 
increased affinity for p63/p73 [12-14, reviewed in 15]. 
In addition, the three family members are linked through 
a microRNAs-based circuit [16]. Two gain-of-function 
-GOF- mechanisms have been suggested: the first posits 
that an excess of mutp53 interferes with p63/p73 function, 
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by inhibiting DNA-binding following a stimulus, or 
forming inactive aggregates [17]. In the second, mutp53 
do reach specific DNA targets, either through protein-
protein interactions with other TFs, such as NF-Y, E2F1, 
NF-KB and VDR [18-21], or via p63-guided interactions 
[22, 23]. Note that “indirect” promoter recruitment of a TF 
by interactions with another TF bound to its element was 
first described for the Estrogen Receptor on Fos/Jun sites 
two decades ago [24], and further detailed for many other 
TFs ever since. The relative “weight” of the two scenarios 
is unclear. To examine this, we decided to explore mutp53 
in vivo DNA-binding and functional activities, and relate 
it to p63 locations in HaCaT cells. 
RESULTS
Mutp53 proteins are highly expressed in HaCaT 
cells [15], as it often the case with other missense mutp53 
alleles: we inactivated the two alleles by stably expressing 
an shRNA under puromycin selection, in parallel with 
a control scramble shRNA. The p53 shRNA targets the 
DNA-binding domain, hence it is aimed at all possible 
isoforms of p53 [25]. Clones were selected, pooled and 
mRNA and protein levels of mutp53 and p63 controlled 
by qRT-PCR and Western blot: Fig. 1A shows that 
mutp53 mRNA levels are substantially decreased, the 
protein levels essentially abolished (Fig. 1B). p63 mRNA 
was modestly decreased. Note that a similar inactivation 
experiment attempted with p63 shRNAs repeatedly failed 
to yield colonies, likely because of the key role of p63 in 
HaCaT survival and growth (EM, RM, unpublished). We 
studied a few parameters of mutp53-expressing and non 
expressing HaCaT, before and after UVB irradiation. As 
shown in Fig. 1C, we noticed a modest variation in cell 
cycle progression: increase in subG1 and G1 cells, and a 
decrease in G2/M in mutp53-depleted cells. The degree 
of apoptosis, as measured by TUNEL assays (Fig. 1D), 
PARP activation and Caspase 8 cleavage (Fig. 1E) was 
lower in the absence of mutp53, but still present. Thus 
other mechanisms compensate for the lack of mutp53 
to drive a DNA-damage response. The most notable 
difference, however, was the growth rate, as curves were 
flatter in HaCaT deprived of mutp53 (Fig. 1F). These data 
confirm that mutp53 are indeed GOF alleles contributing 
to cellular growth.
To investigate the GOF mechanism, we performed 
analysis of p63 and mutp53 binding to genomic locations 
by ChIP-Seq experiments, using the DO1 monoclonal, 
recognizing the N-terminal domain of p53, and a 
polyclonal against p63. We identified 7135 peaks of 
mutp53 and 3421 of p63 in HaCaT cells, defined as areas 
with a significant enrichment in the IP with respect to the 
corresponding genomic region of Input DNA controls 
run in parallel (see Methods). The lists of locations and 
transcription Units are in Supplementary Tables 1 and 2, 
respectively. Notorious p63 targets such as the p21 and 
MDM2 promoters were among the positives (See below). 
We validated the data by using different antibodies, the 
Ab7 p53 polyclonal, which recognizes all p53 isoforms, 
and anti-63 4A4 monoclonal (Supplementary Fig. 1). 
Some of the positive regions in ChIP-Seq were monitored 
by qPCR: with the exception of FANCi, the other targets 
were enriched. We noticed that some targets scoring 
positive only for p63 in ChIP-Seq were also somewhat 
enriched with Ab7, suggesting that we might be 
underscoring the overlap of the two TFs, possibly because 
DO1 is unable to pick up the shorter p53 isoforms present 
in HaCaT cells [25]. Finally, p63 targets previously 
identified as functionally important, such as KLF4, 
Notch1, TP63, DLX3/4 and JAG2, among others, scored 
positive for p63 and mutp53 (Supplementary Fig. 2).
We therefore felt confident to analyze the ChIP-Seq 
locations and found the expected overrepresentation in 
promoters, from -5000 to +1000 of the Transcriptional 
Start Sites (TSS): Fig. 2A shows that 1591 mutp53 
and 907 p63 sites reside in promoters, and 3697 and 
1400, respectively, in the body of RefSeq genes. We 
characterized the overlap between positive peaks, and 
found that 19% of p63 peaks overlap with mutp53 in the 
promoter (175 out of 907) and 17% in the body of genes 
(240 out of 1400). 
Next, we evaluated the enrichment of TFBS in the 
p63+, mutp53+ and p63/mutp53+ peaks with a width of 
150 bp from the center with the Pscan software [26] (Fig. 
2B), using as background a set of 10.0000 sequences of 
the same size, chosen at random from genomic regions 
annotated either as “promoter” or “enhancer”. It is 
apparent that a consensus p53/p63RE is at the top of the 
list in p63+ and p63/mutp53+ peaks, but not in mutp53+, 
where sites of other TFs predominate: E boxes -variously 
termed NHLH1, Myf, Mycn, USF1, MYC-MAX, MAX- 
ESR (nuclear receptors), AP2. This is an indication 
that p63, either alone or with mutp53, recognizes its 
own site, whereas mutp53, in the absence of p63, binds 
DNA through sequences recognized by other TFs. 
We then used the Weeder software [27] to perform de 
novo motif discovery in the peaks of the three cohorts, 
in promoters, genes or elsewhere: Fig. 2C shows that 
a TGGGCATGTC sequence clearly emerged in p63+, 
containing a perfect p53/p63 consensus (underlined), 
with additional information on the flankings; a similar 
sequence, lacking the CC at the 3’ end, is recovered in 
p63/mutp53+ locations; in mutp53+ peaks, instead, the 
variety of underlying sequences prevented the emergence 
of a clear consensus by de novo analysis, confirming the 
underlying presence of several unrelated TFBS. 
A large number of genomic locations of p63 were 
recently reported in primary keratinocytes -PHK- using 
the same antibody employed here [28]. We analyzed the 
data of PHK and HaCaT and found that a substantial 
number -50%- of HaCaT locations are missing in 
primary keratinocytes (Fig. 3). We assessed the number 
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of mutp53 peaks in the two populations and found some 
skewing: 222 were in the PHK common sites, and 367 in 
the HaCaT-only cohort, suggesting that the presence of 
mutp53 alters p63 binding to a subset of sites bound in 
normal keratinocytes. Gene Ontology analysis retrieved 
terms such as organ morphogenesis, tissue and epidermic 
development and positive regulation of transcription in 
p63+ devoid of mutp53 (Fig. 3); the same terms were 
present in the larger p63+ cohort, with the addition of 
Wnt signaling and induction of apoptosis. Terms related 
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Figure 1: Effect of functional inactivation of mutp53 in HaCaT cells. (A) mutp53 was inactivated by transduction of the HaCaT 
cells by lentiviral vector expressing shp53 and vector expressing scramble shRNA served as a negative control. After puromycine selection 
clones were selected, pooled and protein levels of mutp53 and p63 were analyzed by Western blot. Vinculin was used as a loading control. 
(B) mRNA levels of mutp53 and p63 were subsequently controlled by qPCR. Normalization of cDNA templates was achieved by GAPDH 
quantification. (C) Inactivation of mutp53 in HaCaT cells leads to the modest variation of cell cycle progression. The medium of HaCaT 
cells was replaced by PBS and the cells were exposed to 20 mJ/cm2 and 40 mJ/cm2 concentration of UVB light. After UVB treatment PBS 
was replaced to growth medium and after 12h of incubation at the standard conditions cells were harvested and cell cycle progression 
was analyzed by FACS. PBS-treated cells without UVB treatment served as negative control. (D) mutp53 deprived HaCaT cells are less 
sensitive to the apoptosis. shp53 and shscramble HaCaT cells were treated with UVB irradiation and degree of apoptosis was measured 
by TUNEL assay (E) as well as PARP activation and Caspase 8 cleavage were controlled by Western blot. (F) mutp53 affects significantly 
the growth properties of the cells.  Cell growth rates of shp53 and shscramble HaCaT were compared by direct counting of viable cells.
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to signal transduction and cell cycle were prevalent in 
mutp53+ genes (Fig. 3). Specifically, the mutp53/p53+ 
sites were enriched in terms of Wnt signalling and other 
metabolic terms in the molecular function analysis, 
such as actin binding, Tyrosine Kinase and GTPase 
activity. In addition to previously characterized targets 
(Supplementary Figure 3a, b), families of targets worth 
mentioning are Wnt genes -Wnt4, Wnt7a, Wnt9a, Wnt10a- 
and Retinoic Acids Receptors, RARα, RARγ and RXRα 
(Supplementary Fig. 3c, d). Both p63 and mutp53 are 
present at multiple locations of the large cluster of keratin 
genes on chromosome 17, particularly in a conserved 
region at 3’, overlapping with positive epigenetic marks 
(Supplementary Fig. 3e). In general, the p63 and mutp53 
locations overlap with those of histone post-translational 
modifications (Supplementary Fig. 3): although firm 
conclusions are difficult to make because of the difference 
in the cellular contexts of the ChIP-seq profiles, this is 
a further indication that the sites identified here are 
functionally relevant. From this set of data, we conclude 
that p63 binding in HaCaT is different from PHK, in 
part due to the coresidency of mutp53, and that the latter 
recognizes a large set of functionally distinct groups of 
genes independently from p63. 
Next, we performed profiling analysis of mutp53-
inactivated HaCaT cells. A large number of genes were 
up -1649- or down -1644- regulated, by using a relatively 
stringent cut-off ratio of 1.5-fold (Supplementary Table 
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Figure 2: ChIP-Seq analysis of p63 and mutant p53 binding in HaCaT keratinocytes. (A) Distribution of the site position 
for mutp53 and p63 as well as the overlap between p63 and mutp53 positive peaks are present (UCSC genes http://genome.ucsc.edu/). Also 
the number of promoters or genes, positive for at least one peak of mutp53 or p63 or both is indicated.  (B) Evaluation of TFBS enrichment 
in the of p63+, mutp53+ and p63/mutp53+ promoters using Pscan software. (C) Analysis of p63+ and p63/mutp53+ binding site sequences by 
de novo motif discovery performed using the Weeder tool (26).
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Figure 3: p63 and mutant p53 binding in normal and HaCaT keratinocytes.  The comparison of p63 and mutp53 DNA binding 
sites in HaCaT cells and p63 DNA binding sites in PHK.   222 sites were common for p63, mutp53 in HaCaT and p63 in PHK, but the 
comparison also revealed other 367 sites that were shared by p63 and mutp53  just in the HaCaT cells. Gene Ontology analysis for p63+, 
mutp53+, p63+/mutp53+  p63+/mutp53-  in HaCaT keratinocytes is present.
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3). A quick inspection of the genes identified known p53 
targets, such as CDC20, Aurora KinaseA and B, Chek1, 
Topo IIα, CyclinB1 and B2, CyclinA, CDC2, p57/Kip2. 
G2/M genes are normally repressed upon DNA-damage in 
cells harboring wt p53, and regulated in an opposite way 
by indirect recruitment by mutp53 [29, 30]. We validated 
the profiling results by qRT-PCR (Fig. 4A): essentially all 
genes changed expression according to expectations; the 
degree of variation was greater in qRT-PCRs with respect 
to profiling data, which is a common finding, indicating 
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Figure 4: Profiling of mutp53 inactivated HaCaT cells. (A) Validation of microarray data by qPCR. (B) GO analysis:  for the up-
regulated genes cell cycle, as well as DNA and RNA metabolisms and response to DNA-damage categories were retrieved with significant 
p-value, while for down-regulated genes sterol biosynthesis and keratinocyte differentiation categories were obtained even if with the less 
significant p-value. (C) Examples of the genes that are up-regulated and down-regulated by mutp53 removal subdivided regarding their 
belonging to the specified GO category. 
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that we underscored the effect of mutp53 removal in 
our profiling analysis. The overlap between the mutp53 
locations and gene expression analysis is robust -15%- but 
not absolute (DD, RM, unpublished). Some genes might 
be indirectly affected by mutp53 removal, and some of 
the targets are oblivious of its removal, at least in growing 
HaCaT cells. GO categorization identified cell cycle, as 
well as DNA and RNA metabolisms and response to DNA-
damage as robustly enriched in the upregulated cohorts 
(Figure 4B); in the downregulated genes, p values were 
less significant with sterol biosynthesis and keratinocyte 
differentiation being somewhat enriched. Examples of 
genes of up and down-regulated categories are shown in 
Figure 4C. 
DISCUSSION
Our work addresses a debated topic concerning the 
mechanisms of action of GOF mutant p53 and p63. We 
found that (i) mutp53 HaCaT alleles are pro-growth and 
mutp53 have thousands of binding sites in the human 
genome;(ii) they affect gene expression profoundly, both 
by binding with p63 to consensus elements and by being 
tethered by other TFs to their locations. 
Mice deficient for TP53 develop tumors resembling 
SCC after UV irradiation, and other models harboring 
mutp53 alleles have aggressive features in their epithelial 
tumors, including increased capacity to metastatize. 
Hence the hypothesis that certain mutations are GOF has 
visibly gained ground [10,11]. Specific mutations of p53 
alleles are a hallmark of SCC in humans [7]: although 
HaCaT cells are not tumorigenic in vivo, they harbour 
two alleles that are routinely found in SCC, in addition 
to large amount of a fully functional ∆Np63α, the most 
abundant isoform found in human keratinocytes: stable 
p63 inactivation in HaCaT, in fact, was impossible, 
presumably because it is required for cellular growth. 
Instead, inactivation of mutp53 led to suboptimal growth 
rates and a large change in gene expression, as shown in 
previous experiments [31], making the system suitable to 
study p63 in the presence of high amounts of mutp53. 
Mechanistically, two models were proposed: (i) 
mutp53 sequesters tumor suppressors, including p63, in 
inactive complexes, or it inhibits its DNA-binding capacity 
[15, 17]; (ii) mutp53 acts as a bona fide transcription 
factor with a “deviant” specificity, through unrelated TFs, 
or the related p63/p73 [18-22]. Widespread inhibition of 
p63 DNA binding by p53 DNA-binding mutants seems 
to be ruled out by our experiments: >3400 p63 locations 
are retrieved in a cellular context with very high levels of 
tumor-type mutp53, up to 20-fold excess with respect to 
p63 [15]. The same conclusion is reached by analyzing 
gene expression profilings of overexpressed mutp53 in 
p53 null cells: Neilsen et al. find binding of mutp53 to 6 
overexpressed genes [23]. Thus, at the heart of the mutp53 
strategy there are interactions with p63, and with other 
TFs. Interestingly, the p63 locations are partially different 
from the ones found in normal keratinocytes [28], with 
>1700 “new” sites, showing an enrichment of mutp53 
coresidency. In summary, the two previous scenarios for 
mutp53 GOF function, both involving tethering to DNA 
regulatory elements either with p63 (or p73), or via other 
TFs, are operational (Fig. 5). We attempted to “measure” 
the two mechanisms, and the second appears to be 
prevalent, but one needs to be very cautious and aware of 
the bias related to the antibodies used in the analysis: this 
is particularly relevant for mutp53, since DO1 is oblivious 
of the mut53 short isoforms very recently described by the 
lab of JC Bourdon in HaCaT [25]. The picture is therefore 
likely to be more complex.  
The most abundant TFBS scored in the p63 peaks 
is indeed the p53/p63 RE, as found in Pscan analysis 
and in the stringent de novo motif discovery by Weeder, 
confirming that DNA-binding is direct through sequence-
specific contacts and that p63 is functional. Our Weeder-
derived logo incorporates the core central tetranucleotide, 
CANG from Chip on chip analysis of p63 and p73 [32, 33] 
and CNTG from SELEX [34]; it does provide additional 
information in the flankings, and the retrieved decamer is, 
Gene A Gene B
Gene C
p63 p63
p63 p63
p63
p63
p53
mutp53
mutp53
TFs
Gene A Gene B
wt p53
mutp53
?
p53RE p53RE
p53RE p53RE
p53RE E, GC, HR
Figure 5: Models of p63 and mutp53 binding to different classes of promoters.
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to the best of our knowledge, the most detailed p63/p53 
matrix characterized so far. In the mutp53/p63 loci, the 
p53/p63 logo is also obvious, both in Pscan and de novo 
motif discovery; the precision of the ChIP-Seq technique 
allows us to conclude that the two TFs, which are bound 
within 50 bp, share the same DNA motif. If anything, 
tandem elements with variable spacing are enriched in 
the p63, but not mutp53/p63 cohorts: in the latters, it 
is unclear whether mutp53 contacts with DNA have a 
different specificity, or lack it. In general, these data are 
consistent with a model whereby heteromers, formed by 
the observed increased affinity of mutp53 for p63 [12-14], 
and/or higher protein concentrations, are steered to DNA 
by the p63 sequence-specific capacity. Another aspect that 
has not been investigated so far is the reciprocal interplay 
between p63 and wt p53 after DNA-damage in normal 
cells (Fig. 5): one could imagine, in fact, that the binding 
of p63 might serve as a “guide” for an activated p53 to 
find its locations, or at least some of them, during the 
stress response.
As to tethering of mutp53 via unrelated TFs, the 
lack of a single, clearly recognizeable logo with de novo 
motif analysis strongly indicates that multiple TFs are 
involved. Even allowing a high degree of freedom, so 
that “non canonical” sites could be scored [35], we could 
not come up with any enriched motif. Among the TFBS 
previously reported to be guiding mutp53 binding, the NF-
Y, E2F and NFkB sites [18-20] are statistically enriched 
in the profiling data (Supplementary Fig. 4). In the ChIP-
Seq dataset, we do find the Estrogen Receptor, whose 
reciprocal interplay with mutp53 is well documented in 
other epithelial contexts, for example in breast cancer 
cells [36]. Note that HaCaT do not express ERs (EM, 
RM, unpublished), but an identical DNA motif is shared 
with other nuclear receptors, including VDR, recently 
shown to be enriched in ChIP on chip analysis of SKbR3 
cells carrying the -175 p53 GOF mutant [21]. Therefore, 
our data suggest that mutp53 targets nuclear receptors. 
GC boxes, E-boxes, AP2 predominate in ChIP-Seq and 
profilings. E boxes are recognized by a plethora of HLH 
B-Zip proteins, some of which are known to play a role 
in epithelial cancer, including in the skin [37]. GC boxes 
are often overrepresented in many such studies, not least 
because promoters are embedded in CpG islands: this 
box is targeted by zinc fingers TFs belonging to the large 
Sp1 and KLFs family, numbering over 20 members [38]. 
We have recently detailed that one of these -KLF4- is 
targeted by mutp53, through p63 [22]. A large body of 
genetic, biochemical and histopathological evidence 
points to disregulation of KLF4, KLF5 and KLF6 as 
important in the progression of epithelial tumors. The 
lack of previously identified motifs -NFkB, NF-Y, E2F- 
in the ChIP-Seq dataset is not surprising, considering that 
the mutant p53 alleles and the cellular context used here 
are different: this raises the possibility that the set of TFs 
tethering mutp53 might be specific for mutp53 alleles and/
or for a particular cell-type, whether in immortalized or 
transformed conditions. 
As a whole, the p63 preferred GO categories are 
a variation of morphogenesis, tissue and development 
themes, as expected from a master ectodermal regulator; 
clustering of the normal keratinocytes and HaCaT 
p63 locations tells a similar story, with targets in the 
RNA metabolism and transcription category, which we 
previously reported. Mutp53, however, visibly changed 
the configuration, since the mutp53+, as well as the 
common mutp53/p63+, are shifted toward and enrichment 
of signaling, cell-cycle regulation and metabolic terms. As 
for single pathways, those that were previously pinpointed 
-FGF-R, EGF-R, Wnt, Notch- are confirmed. At least 
one previously unappreciated group of genes emerged: 
RARα, RARγ and RXR genes are targeted at multiple 
locations both by p63 and mutp53. Interestingly, genetic 
experiments in mice using a dominant negative RARα 
expressed in basal keratinocytes via the K14 promoter 
caused inhibition of endogenous RARα and RARγ with 
greatly diminished p63 levels: this led to a dramatic skin 
phenotype very similar to the one found in p63 KO mice 
[39]. Given the general anti-proliferative properties of 
RARs, including in the skin [40], the intersection of p63/
mutp53 with RARs is certainly worth more exploration in 
the future, particularly in tumors.
In summary, our data support the idea that p53 
mutants do affect growth by altering gene expression via 
specific binding to discrete DNA elements, in promoters 
and elsewhere, either through p63, or selected classes of 
TFs. Furthermore, the normal p63 regulome is altered, 
and mutp53 partially diverts p63 activity to locations not 
normally seen in normal keratinocytes. Our work should 
be extended to different cellular contexts, in tumorigenic 
cells carrying different GOF mutp53 and splicing isoforms 
of p63 as well as the related p73.
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MATERIALS AND METHODS
Cells and Infections
Human HaCat keratinocytes were maintained in 
DMEM supplemented with 10% FCS, 2 mM glutamine 
and 100 U penicillin/streptomycin. The growth 
characteristics were obtained by counting the cells in the 
hemacytometer at the indicated time points. For UVB 
irradiation, 80% confluent HaCaT cells was replaced by 
PBS and the cells were exposed to various concentrations 
(20mJ/cm
2
, 40mJ/cm
2
) of UVB light emitted by MacroVue 
UV-20 (Hoefer, USA) with the peak at 320 nm. After 
removal of PBS the growth medium was added and the 
cells were incubated for 12 h at normal conditions and 
then harvested with cell scraper including those floating in 
medium. PBS-treated cells without UVB treatment served 
as negative control.
For the cell cycle analysis 106 cells were washed 
once in PBS and then fixed with 70% cold ethanol. After 
this one wash in 1% BSA in PBS was performed and the 
cells were stained for 30’ in 1ml of PI solution (20μg/ml 
Propidium Iodide, 10μg/ml Rnase solution in PBS). The 
data were acquired by FACS within 2 h after staining. 
TUNEL assay for detection of apoptosis was performed 
according to the manufacturer’s protocol (Roche 
Applied Science, Germany). The cells were fixed for 1h 
in 4% Paraformaldehyde in PBS, rinsed with PBS and 
permeabilised for 2’ in 0,1% Triton X-100 in 0,1% sodium 
citrate. After 2 washes with PBS cells were stained with 
50 μl of TUNEL reaction mixture and then with DAPI and 
the cells were immediately analysed under a fluorescence 
microscope. 
For the lentivirus production one day before 293T 
cells were split at the density of 5*106 cells per plate 
using 20 ml of DMEM medium supplemented with 10% 
FBS. For the 3 plasmid system the following DNA mix 
was prepared: 20μg lentiviral vector, 10μg VSVG, 15μg 
Δ3.8. In the tube with DNA, 400μl of 1,25 MCaCl
2
  and 
1,5ml of H
2
O were added; 2ml of 2X HBS (280mM 
NaCl, 50mM Hepes, 1,5mM Na
2
HPO4, pH 6,95) were 
added. The transfection mixture was kept 12h after 
which the medium was changed. After 36h, the viral 
supernatant was harvested and filtered through a 0,45μm 
filter. The lentiviral infection of HaCaT cells were 
performed by double spinoculation of 70% confluent 
cells (1h centrifugation, 2000 rpm, with a 5h interval) in 
the presence of 2 μg/ml polybrene. 72 h after infection 
puromycine (Sigma, USA) was added in the medium for 
selection. For p53 knockdown in the HaCaT cells, the 
shp53 pLKO.1 puro plasmid (Addgene, USA) was used 
and shscramble pLKO.1 puro plasmid was used as control. 
After 3 weeks in the selection medium, stable clones were 
pooled. 
Western blot analysis was perfomed according to 
standard procedures with whole cell extracts with DO1 
anti-p53, anti-p63 (Genespin, Italy), anti-vinculin (Sigma, 
USA), anti-cleaved Caspase 8 (Cell Signaling Technology, 
USA) and anti-PARP (Santa Cruz, USA) antibodies. 
ChIP and ChIP-Seq
ChIP was carried out as previously described (21). 
In brief, about 5 mg of chromatin (equivalent to 18 
x 150 mm dishes with cells at 80% confluence) were 
used in IP experiments, with either mouse monoclonal 
anti-p53 (DO1), or rabbit polyclonal anti-p63 antibodies 
(Genespin, I). Each chromatin set was divided into 10 
aliquots, which in turn were independently IPed using 
10µg of the appropriate antibody. In parallel, 500 µg of 
chromatin were IPed with 10 g of mouse monoclonal 
anti-Flag antibody (Sigma) as a control. ChIP-enriched 
and their Unbound fractions were recovered and 
subject to crosslink reversal, proteinase K digestion, 
phenol/chloroform extraction, DNA precipitation and 
quantitation. Single ChIP-enriched DNA samples were 
then tested by qPCR to assess enrichment on known 
targets of either p53 and/or p63. p63 enrichment (mean ± 
SD) on Myoneurin promoter and C40 enhancer were 2.76 
± 0.46 and 49.88 ± 18.61, respectively; p53 enrichment on 
LEF1 upstream region were 1.74 ± 0.34 and 7.05 ± 2.12. 
ChIP-enriched DNAs, as well as half of the corresponding 
Unbound DNAs, were pooled together, precipitated and 
quantitated. 50 ng of each ChIP-enriched or Unbound 
DNA were then converted into a library suitable for 
high-throughput sequencing using an Illumina Genomic 
Analyzer following the manufacturer’s istructions. Before 
sequencing, amplified ChIP-samples were tested in 
parallel to amplified Unbound, pre-amplification ChIP-
enriched, and pre-amplification Unbound DNAs, to score 
for enrichment. Sequence reads were mapped to the 
masked human genome sequence (assembly GRCh37, 
retrieved from the UCSC genome browser database (38) 
using the Seqmap tool (39). Matched was performed 
by allowing at most two mismatches at any position of 
the reads. Trimming unmapped reads at the 3’end led to 
marginal improvements in the number of mapped reads 
and this step was therefore skipped. Only reads mapping 
to a unique position on the genome were considered for 
further analysis. This resulted in about 10 million uniquely 
mapping reads for each of the two mutp53 experiments 
(IP and input) and in about 4 million for each of the two 
p63 experiments. In each experiment, uniquely mapped 
reads were then extended by 300 bps along the 5’->3’ 
direction. This produced, for each ChIP or input sample, 
a base pair by base pair coverage map of the genome, 
that is, giving for each base pair the number of extended 
sequence reads that contained it. Only base pairs covered 
by reads mapping on both strands were considered valid 
for further analysis. Enrichment was then calculated in 
Oncotarget 2012; 3:  132-143141www.impactjournals.com/oncotarget
each valid base pair by comparing, for each IP experiment, 
the coverage in the experiment to the coverage in the 
respective input used as expected value, and computing an 
enrichment p-value with a negative binomial distribution. 
Enriched regions were then defined as regions consisting 
of consecutive base pairs characterized by calculated 
p-values smaller than 0.01 and not interrupted by a gap of 
100 bps or more non valid or with a p-value greater than 
0.01. The p-value associated with each of the enriched 
regions was defined as the minimum p-value among the 
base pairs belonging to the region. Regions shorter than 
150 bps were then discarded regardless of the p-value. 
The p-value associated with the remaining regions was 
then used to compute the false discovery rate (FDR) with 
the Benjamini-Hochberg correction. This resulted in 7136 
regions for p53 and 3422 for p63 with FDR lower than 
0.01.
To further validate the predicted regions we applied 
the MACS tool (40) to the same datasets, with default 
parameters. About 95% of our predicted regions in 
both mutp53 and p63 experiments were also found as 
significantly enriched by MACS at p-value 10-6 (roughly 
corresponding to our False Discovery Rate of 0.01).
RNA Profiling
Total RNA was extracted using RNeasy Mini kit 
(Qiagen, D) according to the manufacturer’s protocol. 
For qPCR analysis, 1μg of RNA was reverse-trascribed 
using Reverse Transcription System (Promega, USA). 
The expression level for each gene was normalized 
with GAPDH. The list of the primers used for qPCR 
is shown in Supplementary 4. For profiling, RNA 
quality was assessed using an Agilent 2100 Bioanalyzer 
(Agilent Technologies, USA). 500 ng of total RNA was 
synthesized to biotinylated cRNA using the Illumina 
RNA Amplification Kit (Ambion, USA). 750 ng cRNA 
was hybridized for 18 h to HumanHT12 v. 3.0 Expression 
BeadChips (Illumina USA) according to the protocol 
provided by the manufacturer. Hybridized chips were 
washed and stained with streptavidin-conjugated Cy3 
(GE Healthcare, USA). BeadChips were dried and 
scanned with an Illumina BeadArray Reader (Illumina 
Inc.) and analyzed with the Illumina BeadStudio v. 
3.1.3.0 software. The quantile normalization algorithm 
was applied on the data set to correct systematic errors. 
Background was subtracted. For differential expression 
analysis, three technical replicates of each sample were 
grouped together and genes with a detection of p-value 
<0.01, corresponding to a false-positive rate of 1%, were 
considered as detected. Differently expressed genes were 
selected with Diff Score cutoff set at ±30, corresponding 
to a P-value of 0.001.
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